Imagen de Portada

KleistLab/PrEP_Truvada: PrEP_Truvada (women & MSM)

Fuente: Zenodo

Guardado en:

Detalles Bibliográficos
Autores principales:	lanmao46, SaraIannuzzi, Kleist Lab
Formato:	Recurso digital
Publicado:	Zenodo 2026
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Transforming PrEP marketing: understanding the place of PrEP in the hearts and minds of adolescent girls and young women in sub‐Saharan Africa
por: Emily de Lacy Donaldson, et al.
Publicado: (2025)

Paradoxes of PrEP for HIV Prevention
por: Skovdal, Morten
Publicado: (2025)

Improving PrEP access for adolescent girls and young women: a descriptive analysis of community‐based PrEP delivery in the DREAMS programme in Zambia
por: Maurice Musheke, et al.
Publicado: (2025)

Dosing forgiveness of oral PrEP for cisgender women remains uncertain
por: Mia Moore, et al.
Publicado: (2025)

Driving progress towards PrEP equity: Key changes in the 2025 BASHH/BHIVA UK PrEP guidelines
por: Dan Clutterbuck, et al.
Publicado: (2025)

PrEP use and willingness cascades among GBMSM in 15 Asian countries/territories: an analysis of the PrEP APPEAL survey
por: Gede Benny Setia Wirawan, et al.
Publicado: (2025)

Reconstructing MSM Sexual Networks to Guide PrEP Distribution Strategies for HIV Prevention
por: Brázia, João, et al.
Publicado: (2026)

Assessing pharmacy students' HIV pre‐exposure prophylaxis (PrEP) prescribing knowledge, PrEP attitudes, and HIV‐related stigma
por: Celeste Noelle Bustria, et al.
Publicado: (2024)

Exploring perceptions and preferences for PrEP choice and of an mHealth intervention: insights from the ImPrEP CAB‐Brasil study
por: Cristina Pimenta, et al.
Publicado: (2025)

Correction to PrEP use and willingness cascades among GBMSM in 15 Asian countries/territories: An analysis of the PrEP APPEAL survey
Publicado: (2025)

Modelling the impact of initiation delay, duration and prior PrEP on the efficacy of post‐exposure prophylaxis containing a tenofovir/emtricitabine backbone
por: Lanxin Zhang, et al.
Publicado: (2025)

Pharmacokinetics, Pharmacodynamics, Efficacy and Drug Resistance Selection of Injectable Long‐Acting Lenacapavir Pre‐Exposure Prophylaxis ( PrEP ) Against HIV
por: Hee‐yeong Kim, et al.
Publicado: (2026)

PrEP choice in the real world: Results of a prospective cohort study describing uptake and use patterns of oral PrEP and the dapivirine vaginal ring among women in sub‐Saharan Africa
por: Virginia A. Fonner, et al.
Publicado: (2025)

PrEP at the site of action in cisgender and transgender women: A pharmacology study of blood and rectal CD4 + lymphocytes
por: Elizabeth Hastie, et al.
Publicado: (2026)

Determinants of HIV pre‐exposure prophylaxis (PrEP) use among men who have sex with men (MSM) living in rural areas of the United States: A scoping review framed by the PrEP care continuum
por: Andrew M. O'Neil, et al.
Publicado: (2025)

Finally, PrEP choices! But will clients ever have a choice?
por: Kimberly E. Green, et al.
Publicado: (2025)

High acceptability, feasibility and sustainability of a direct‐to‐pharmacy differentiated PrEP delivery model in public health HIV clinics in Kenya: perspectives of PrEP clients and healthcare providers
por: Emmah Owidi, et al.
Publicado: (2025)

Sexual behaviour and STIs among MSM living with HIV in the PrEP era: the French ANRS PRIMO cohort study
por: Virginie Baltes, et al.
Publicado: (2024)

Analytical and numerical methods for spillover effects in prioritized PrEP for HIV prevention
por: Piazzola, Chiara, et al.
Publicado: (2025)

Seizing the moment: the potential of PrEP choice and innovation to transform HIV prevention
por: Heather‐Marie A. Schmidt, et al.
Publicado: (2025)

Role of the pharmacist in pre-exposure chemoprophylaxis (PrEP) therapy for HIV prevention
por: Kevin A. CLAUSON
Publicado: (2009)

Pre-exposure prophylaxis (PrEP) against HIV: efficacy, safety and uncertainties
por: Matilde Sánchez-Conde
Publicado: (2017)

Facilitators and barriers to community pharmacy PrEP delivery: a scoping review
por: China Harrison, et al.
Publicado: (2024)

“People have options”: a qualitative study of experiences and influences of PrEP choice among women in South Africa
por: Siphokazi Dada, et al.
Publicado: (2025)

High syphilis incidence among PrEP‐adherent men who have sex with men and transgender women in Peru
por: Silver K. Vargas, et al.
Publicado: (2025)

Findings from the ‘Ask Me About PrEP’ HIV Pre‐Exposure Prophylaxis Awareness Programme in England
por: Jonny Edwards, et al.
Publicado: (2024)

Towards More Accessible and More Inclusive PrEP to Break the Cycle of HIV in France
por: Jade Ghosn, et al.
Publicado: (2026)

Defining HIV Pre‐Exposure Prophylaxis (PrEP) Persistence: A Scoping Review
por: Sarah E. Rutstein, et al.
Publicado: (2026)

Informal PrEP use in Greece: The long, hard road to formal programmatic implementation
por: Konstantinos Protopapas, et al.
Publicado: (2025)

Testing Paradox May Explain Increased Observed Prevalence of Bacterial STIs among MSM on HIV PrEP: A Modeling Study
por: Müller, Laura, et al.
Publicado: (2025)

Achieving reimbursable PrEP is insufficient to increase and diversify the users attending community‐based services
por: Enrico Caruso, et al.
Publicado: (2026)

A Scoping Review of Biobehavioural Interventions to Improve PrEP Continuum of Care in Latin America
por: Vanessa Sánchez-Mendoza
Publicado: (2023)

Characterizing HIV seroconversions among a cohort of oral PrEP users in South Africa
por: Catherine E. Martin, et al.
Publicado: (2025)

Characterizing populations prioritized for PrEP in 19 African countries: a review of national guidance
por: Lauren A. Graybill, et al.
Publicado: (2025)

Expanding access to a choice‐based multi‐method PrEP market for HIV prevention
por: Nicolette P. Naidoo, et al.
Publicado: (2025)

Cost‐effectiveness of leveraging long‐acting injectable cabotegravir to expand PrEP coverage among MSM in two contrasting North American cities
por: Jesse A. Heitner, et al.
Publicado: (2026)

Strategies for implementing long‐acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study
por: Katherine L. Nelson, et al.
Publicado: (2025)

PrEP preferences and early acceptability of injectable cabotegravir among pregnant and lactating people in Cape Town, South Africa: findings from the PrEPared to Choose study
por: Nafisa Wara, et al.
Publicado: (2025)

Estimated impact of long‐acting injectable PrEP in South Africa: a model comparison analysis
por: Sarah E. Stansfield, et al.
Publicado: (2025)

Data and Code: Bridging the Gap — The PrEP Cascade Paradigm Shift for Long-Acting Injectable HIV Prevention
por: Demidont, AC
Publicado: (2026)